0001535385-20-000003.txt : 20200121
0001535385-20-000003.hdr.sgml : 20200121
20200121091438
ACCESSION NUMBER: 0001535385-20-000003
CONFORMED SUBMISSION TYPE: SC 13G
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20200121
DATE AS OF CHANGE: 20200121
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Artemis Investment Management LLP
CENTRAL INDEX KEY: 0001535385
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-89706
FILM NUMBER: 20535260
BUSINESS ADDRESS:
STREET 1: 42 MELVILLE STREET
CITY: EDINBURGH
STATE: X0
ZIP: EH3 7HA
BUSINESS PHONE: 011441317180407
MAIL ADDRESS:
STREET 1: 42 MELVILLE STREET
CITY: EDINBURGH
STATE: X0
ZIP: EH3 7HA
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Artemis Investment Management LLP
CENTRAL INDEX KEY: 0001535385
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
BUSINESS ADDRESS:
STREET 1: 42 MELVILLE STREET
CITY: EDINBURGH
STATE: X0
ZIP: EH3 7HA
BUSINESS PHONE: 011441317180407
MAIL ADDRESS:
STREET 1: 42 MELVILLE STREET
CITY: EDINBURGH
STATE: X0
ZIP: EH3 7HA
SC 13G
1
Artemis2019.htm
Schedule 13G
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Bioxcel Therapeutics Inc
(Name of Issuer)
Please enter the share class name
(Title of Class of Securities)
09075P105
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
(X) Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 09075P105
1.
Names of Reporting Persons.
Artemis Investment Management LLP
2.
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) (b)
3.
SEC Use Only
4.
Citizenship or Place of Organization
GB
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
5.
Sole Voting Power
1,073,591
6.
Shared Voting Power
0
7.
Sole Dispositive Power
1,073,591
8.
Shared Dispositive Power
0
9.
Aggregate Amount Beneficially Owned by Each Reporting Person
1,073,591
10.
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions)
11.
Percent of Class Represented by Amount in Row (9)
6.0%
12.
Type of Reporting Person (See Instructions)
FI
Item 1.
(a)Name of Issuer
Bioxcel Therapeutics Inc
(b)Address of Issuer's Principal Executive Offices
555 Long Wharf Drive, 12th Floor, New Haven, CT, 06511, United States
Item 2.
(a)Name of Person Filing
Artemis Investment Management LLP
(b)Address of Principal Business Office or, if none, Residence
Cassini House, 57-59 St. James's Street, London, SW1A 1LD, United Kingdom
(c)Citizenship
See Item 4 on the cover page(s) hereto.
(d)Title of Class of Securities
Please enter the share class name
(e)CUSIP Number
09075P105
Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or
(c), check whether the person filing is:
(a) A Broker or dealer registered under Section 15 of the Act (15 U.S.C.
78o);
(b) A Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) An insurance company as defined in Section 3(a)(19) of the Act (15
U.S.C. 78c);
(d) An investment company registered under Section 8 of the Investment
Company Act of 1940 (15 U.S.C. 80a-8);
(e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
(f) An employee benefit plan or endowment fund in accordance with
240.13d-1(b)(1)(ii)(F);
(g) A parent holding company or control person in accordance with
240.13d-1(b)(1)(ii)(G);
(h) A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
(i) A church plan that is excluded from the definition of an investment
company under Section 3(c)(14) of the Investment Company Act of 1940 (15
U.S.C. 80a-3);
(j) X A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
(k) A group, in accordance with 240.13d-1(b)(1)(ii)(K).
Item 4. Ownership.
(a)Amount beneficially owned:
See Item 9 on the cover page(s) hereto.
(b)Percent of class:
See Item 11 on the cover page(s) hereto.
(c)Number of shares as to which such person has:
(i)Sole power to vote or to direct the vote:
See Item 5 on the cover page(s) hereto.
(ii)Shared power to vote or to direct the vote:
See Item 6 on the cover page(s) hereto.
(iii)Sole power to dispose or to direct the disposition of:
See Item 7 on the cover page(s) hereto.
(iv)Shared power to dispose or to direct the disposition of:
See Item 8 on the cover page(s) hereto.
Item 5. Ownership of 5% or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following .
Item 6. Ownership of More than 5 Percent on Behalf of Another Person
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8. Identification and Classification of Members of the Group
Each reporting person may be deemed to be a member of a group with respect to
the issuer or securities of the issuer for the purposes of Section 13(d) or
13(g) of the Act. Each reporting person declares that neither the filing of this
statement nor anything herein shall be construed as an admission that such
person is, for the purposes of Section 13(d) or 13(g) of the Act or any other
purpose, (i) acting (or has agreed or is agreeing to act) with any other person
as a partnership, limited partnership, syndicate, or other group for the purpose
of acquiring, holding, or disposing of securities of the issuer or otherwise
with respect to the issuer or any securities of the issuer or (ii) a member of
any syndicate or group with respect to the issuer or any securities of the
issuer.
Item 9. Notice of Dissolution of Group
Each reporting person may be deemed to be a member of a group with respect to
the issuer or securities of the issuer for the purposes of Section 13(d) or
13(g) of the Act. Each reporting person declares that neither the filing of this
statement nor anything herein shall be construed as an admission that such
person is, for the purposes of Section 13(d) or 13(g) of the Act or any other
purpose, (i) acting (or has agreed or is agreeing to act) with any other person
as a partnership, limited partnership, syndicate, or other group for the purpose
of acquiring, holding, or disposing of securities of the issuer or otherwise
with respect to the issuer or any securities of the issuer or (ii) a member of
any syndicate or group with respect to the issuer or any securities of the
issuer.
Item 10. Certifications
By signing below each signatory certifies that, to the best of his or its
knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or
effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Date: 2020-01-20
Artemis Investment Management LLP
By: Artemis Investment Management LLP,
its General Partner
By:
Name: Ashley Lee
Title: Authorized Signatory
EXHIBIT INDEX
Exhibit
Description of Exhibit
99.1 Joint Filing Agreement